Atrium Therapeutics, Inc. RNA
Atrium Therapeutics, Inc. (Nasdaq: RNA) is a cardio-renal-metabolic drug developer. Its lead program, ATR 1072, is in Pre-clinical for PRKAG2 syndrome. Its next catalyst on record is ATR 1072: First participant enrolled in Corventis Phase 1/2 trial (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ATR 1072 — First participant enrolled in Corventis Phase 1/2 trial (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ATR 1072 | PRKAG2 syndrome | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| ATR 1086 | PLN cardiomyopathy | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| Undisclosed rare cardiomyopathy programs (2) | — | RNA (siRNA/ASO/mRNA) | Pre-clinical |
Recent results and decisions
- Jul 14, 2026n/a FDA cleared IND for ATR 1072 Phase 1/2 Corventis trial in PRKAG2 syndrome (~37 participants).
the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application allowing the Company to move forward with its Corventis™ Phase 1/2 clinical trial
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical cardio-renal-metabolic companies
- Opko Health, Inc. OPK
- Editas Medicine, Inc. EDIT
- Cellectis S.A. CLLS
- NewcelX Ltd. NCEL
- Fractyl Health, Inc. GUTS
- Alaunos Therapeutics, Inc. TCRT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.